PET Imaging

Overview

Positron emission tomography uses radiotracers to image metabolic activity. It provides functional information about tissues. It is often combined with CT or MRI for localization.

Clinical Applications

PET is used in oncology neurology and cardiology. It detects metabolic activity of tumors and brain disorders. It guides therapy selection and response assessment.

Radiotracers

Common tracers include FDG and others for specific targets. Tracer selection depends on clinical question. Radiochemistry advances expand tracer availability.

Hybrid Imaging

PET CT and PET MRI combine functional and anatomic data. These hybrids improve diagnostic accuracy and staging. They are valuable in complex cases.

Advanced PET Tracers

Overview

New PET tracers target specific molecular pathways to improve disease detection. These tracers expand applications beyond standard metabolic imaging. Clinical translation requires validation and regulatory approval.

Clinical Uses

Targeted tracers enable imaging of receptors inflammation and cellular processes. They improve specificity for oncologic and neurologic indications. Tracer selection depends on the clinical question and availability.

Production and Logistics

Radiochemistry and distribution affect tracer accessibility and scheduling. Short half life tracers require local production or rapid transport. Infrastructure investment supports broader clinical use.

Future Directions

Novel tracers paired with hybrid imaging enhance precision medicine. Quantitative PET metrics support therapy selection and monitoring. Ongoing trials will define clinical roles and cost effectiveness.